Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

BACKGROUND: Factor XI (FXI) inhibition offers the promise of hemostasis‐sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymog...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, B. Alexander, Freedholm, Debra, Widener, Nancy, Wang, Xiaohui, Simard, Emilie, Cullen, Constance, Al‐Saady, Naab M., Lepor, Norman E., Coulter, Sara, Lovern, Mark, Bloomfield, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298689/
https://www.ncbi.nlm.nih.gov/pubmed/34714969
http://dx.doi.org/10.1111/jth.15577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298689/
https://www.ncbi.nlm.nih.gov/pubmed/34714969
http://dx.doi.org/10.1111/jth.15577

Ejemplares similares